Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Feb 25

PMID 36831661

Authors

Briana Kinnel

Santosh Kumar Singh

Gabriela Oprea-Ilies

Rajesh Singh

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common cause of cancer-related death in women worldwide. Multidrug resistance (MDR) has been a large hurdle in reducing BC death rates. The drug resistance mechanisms include increased drug efflux, enhanced DNA repair, senescence escape, epigenetic alterations, tumor heterogeneity, tumor microenvironment (TME), and the epithelial-to-mesenchymal transition (EMT), which make it challenging to overcome. This review aims to explain the mechanisms of resistance in BC further, identify viable drug targets, and elucidate how those targets relate to the progression of BC and drug resistance.

Citing Articles

The Adaptation of MCF-7 Breast Cancer Spheroids to the Chemotherapeutic Doxorubicin: The Dynamic Role of Phase I Drug Metabolizing Enzymes.

Crispim D, Ramos C, Esteves F, Kranendonk M Metabolites. 2025; 15(2).

PMID: 39997761 PMC: 11857127. DOI: 10.3390/metabo15020136.

Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers.

Shirani N, Abdi N, Chehelgerdi M, Yaghoobi H, Chehelgerdi M Front Cell Dev Biol. 2025; 13:1485422.

PMID: 39925739 PMC: 11802832. DOI: 10.3389/fcell.2025.1485422.

Metabolomics integrated genomics approach: Understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1/EGFR/PI3k/PTEN crosstalk.

Kadry M, Abd-Ellatef G, Ammar N, Hassan H, Hussein N, Kamel N Toxicol Rep. 2025; 14:101884.

PMID: 39886047 PMC: 11780168. DOI: 10.1016/j.toxrep.2024.101884.

Bilosomal Co-Encapsulated Tamoxifen and Propranolol for Potentiated Anti-Breast Cancer Efficacy: In Vitro and In Vivo Investigation.

Elebyary T, Sultan A, Abu-Risha S, El Maghraby G, Amin M Pharmaceutics. 2025; 17(1).

PMID: 39861770 PMC: 11768151. DOI: 10.3390/pharmaceutics17010123.

Design, synthesis, , and studies of novel isatin-hybrid hydrazones as potential triple-negative breast cancer agents.

Munir I, Batool Z, Khan F, Hussain J, Khan A, Mali S RSC Adv. 2025; 15(2):948-965.

PMID: 39807200 PMC: 11726183. DOI: 10.1039/d4ra07650h.

References

Tzeng H, Yang L, Chen K, Wang Y, Liu Y, Pan S . The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget. 2015; 6(13):11061-73. PMC: 4484439. DOI: 10.18632/oncotarget.3568. View

Lu Y, Im S, Colleoni M, Franke F, Bardia A, Cardoso F . Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2021; 28(5):851-859. PMC: 9377723. DOI: 10.1158/1078-0432.CCR-21-3032. View

Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A . Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021; 13(17). PMC: 8428369. DOI: 10.3390/cancers13174287. View

Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J . Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014; 5:75. PMC: 3942647. DOI: 10.3389/fphys.2014.00075. View

Condorelli R, Spring L, OShaughnessy J, Lacroix L, Bailleux C, Scott V . Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. Ann Oncol. 2017; 29(3):640-645. DOI: 10.1093/annonc/mdx784. View

Linke M, Fritsch S, Sukhbaatar N, Hengstschlager M, Weichhart T . mTORC1 and mTORC2 as regulators of cell metabolism in immunity. FEBS Lett. 2017; 591(19):3089-3103. PMC: 6322652. DOI: 10.1002/1873-3468.12711. View

Krastev D, Li S, Sun Y, Wicks A, Hoslett G, Weekes D . The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin. Nat Cell Biol. 2022; 24(1):62-73. PMC: 8760077. DOI: 10.1038/s41556-021-00807-6. View

Cortesi L, Rugo H, Jackisch C . An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Target Oncol. 2021; 16(3):255-282. PMC: 8105250. DOI: 10.1007/s11523-021-00796-4. View

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

10.

Solzak J, Atale R, Hancock B, Sinn A, Pollok K, Jones D . Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. NPJ Breast Cancer. 2017; 3:17. PMC: 5460220. DOI: 10.1038/s41523-017-0016-8. View

11.

Lloyd R, Wijnhoven P, Ramos-Montoya A, Wilson Z, Illuzzi G, Falenta K . Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020; 39(25):4869-4883. PMC: 7299845. DOI: 10.1038/s41388-020-1328-y. View

12.

Choudhari S, Chaudhary M, Bagde S, Gadbail A, Joshi V . Nitric oxide and cancer: a review. World J Surg Oncol. 2013; 11:118. PMC: 3669621. DOI: 10.1186/1477-7819-11-118. View

13.

Patel A, Unni N, Peng Y . The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers (Basel). 2020; 12(8). PMC: 7464074. DOI: 10.3390/cancers12082081. View

14.

Goel S, Wang Q, Watt A, Tolaney S, Dillon D, Li W . Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016; 29(3):255-269. PMC: 4794996. DOI: 10.1016/j.ccell.2016.02.006. View

15.

Nedeljkovic M, Damjanovic A . Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge. Cells. 2019; 8(9). PMC: 6770896. DOI: 10.3390/cells8090957. View

16.

Bulut A, Erden E, Dizbay Sak S, Doruk H, Kursun N, Dincol D . Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases. Virchows Arch. 2005; 447(1):24-30. DOI: 10.1007/s00428-005-1250-2. View

17.

Appert-Collin A, Hubert P, Cremel G, Bennasroune A . Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol. 2015; 6:283. PMC: 4657385. DOI: 10.3389/fphar.2015.00283. View

18.

Kim Y, Kahn M . The role of the Wnt signaling pathway in cancer stem cells: prospects for drug development. Res Rep Biochem. 2015; 4:1-12. PMC: 4640466. DOI: 10.2147/RRBC.S53823. View

19.

Ali R, Wendt M . The paradoxical functions of EGFR during breast cancer progression. Signal Transduct Target Ther. 2017; 2. PMC: 5397119. DOI: 10.1038/sigtrans.2016.42. View

20.

Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M . Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2016; 36(16):2255-2264. PMC: 5393973. DOI: 10.1038/onc.2016.379. View